Barbara Ann Burtness, MD

Professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program ; Co-Director, Developmental Therapeutics Research Program

Physician Biography

Dr. Burtness received her medical degree from the State University of New York at Stony Brook. She completed her internship and residency at Yale-New Haven Hospital, and a fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Burtness is a member of the American Society for Clinical Oncology and American Association for Cancer Research. She is a member of the editorial board of HemOnc Today, Journal of Clinical Oncology, Frontiers in Oncology, and Clinical Cancer Research. She has authored over 100 peer-reviewed publications.

Clinical Interests

  • Adult
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Yale Cancer Center: Head & Neck Cancers Program

Yale Medicine

Board Certifications

  • Internal Medicine AB of Internal Medicine (1989)

  • Medical Oncology AB of Internal Medicine (1993)

Clinical Trials

Conditions Study Title
Soft Tissue Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Larynx, Lip, Oral Cavity and Pharynx A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Larynx, Lip, Oral Cavity and Pharynx Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lip, Oral Cavity and Pharynx, Soft Tissue A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Larynx, Lip, Oral Cavity and Pharynx Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Lip, Oral Cavity and Pharynx A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
Larynx, Lip, Oral Cavity and Pharynx, Ill-Defined Sites A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Larynx, Lip, Oral Cavity and Pharynx Phase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lip, Oral Cavity and Pharynx Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Larynx, Lip, Oral Cavity and Pharynx Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Lip, Oral Cavity and Pharynx Window Trial 5-aza in HNSCC, T-tare
Lip, Oral Cavity and Pharynx Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Edit this profile

Contact Info

Barbara Ann Burtness, MD
Patient Care Location
Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste NP - 4

New Haven, CT 06511
View on map...
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06520-8028